Benefits and risks of off-label olanzapine use for symptom management in cancer patients—a case report
Annals of Palliative Medicine · 2023
DOI: 10.21037/apm-22-1167 ↗Kurz gefasst
Fallbericht in der Zeitschrift Annals of Palliative Medicine, 2023. Verfasst von Rony Dev und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Symptom Control and Palliative Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Adenocarcinoma, Antiemetics, Pancreatic Neoplasms, Sleep Initiation and Maintenance Disorders. Die Arbeit wurde bisher 13-mal zitiert (Crossref).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Symptom Control and Palliative Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Palliative Care, Sanford USD Medical Center, Sioux Falls, SD, USA.
Zitieren
APA
Dev, R., Fortuno, E. S., Amaram-Davila, J. S., Haider, A., & Bruera, E. (2023). Benefits and risks of off-label olanzapine use for symptom management in cancer patients—a case report. Annals of Palliative Medicine. https://doi.org/10.21037/apm-22-1167
Vancouver
Dev R, Fortuno ES, Amaram-Davila JS, Haider A, Bruera E. Benefits and risks of off-label olanzapine use for symptom management in cancer patients—a case report. Annals of Palliative Medicine. 2023. doi:10.21037/apm-22-1167
BibTeX
@article{Dev2023,
author = {Dev, Rony and Fortuno, Edgardo S and Amaram-Davila, Jaya S and Haider, Ali and Bruera, Eduardo},
title = {Benefits and risks of off-label olanzapine use for symptom management in cancer patients—a case report},
journal = {Annals of Palliative Medicine},
year = {2023},
doi = {10.21037/apm-22-1167}
}
EUVIMED